Pharmaceuticals, Biotechnology & Life Sciences

Discover how OMEROS’ insider buying and strategic focus on joint‑health therapeutics could drive future growth, yet face regulatory and competitive hurdles.

Inside Nuvation Bio’s latest trades: CEO buys shares after a Big sale, hinting at upside from safusidenib’s Fast‑Track approval – what this means for investors.

Quart Barry D’s August 19 gift sale of 2,600 Kiniksa Class A shares shows insider confidence while highlighting potential short‑term volatility amid intense social‑media buzz.

Investors weigh KURA Onco’s CEO’s block sale—31,487 shares at $12.63—seeing it as a routine vesting exit that still signals insider confidence in the biotech’s growth prospects.

Inside ACHIEVE’s insider sale: Stewart Alistair sells 20,626 shares at $8.49, yet retains a major stake—showing liquidity, not loss of confidence, as the biotech climbs after a 141% YTD surge.

SC US (TTGP) buys ATYR Pharma shares, signaling long‑term confidence in its physiocrine biotech platform amid regulatory hurdles and market volatility.

Medpace insider selling rises—CEO Troendle sells 15,609 shares amid a month‑long outflow trend, raising questions about long‑term commitment.

Arcutis Biotherapeutics insider sale shows routine RSU tax‑withholding, not a sell‑off, while the company’s robust SLE drug, IL‑6 pipeline, and $3.33 B market cap keep investor sentiment positive.

CEO Loeillot Olivier’s disciplined 10b5‑1 purchase of 5,426 REPLIGEN shares signals strong management confidence and a long‑term growth outlook for the biotech firm.

HUMACYTE insider buying shows top execs bullish on its bio‑engineered skin grafts, even as the stock slides; explore short‑term momentum vs. long‑term regulatory upside.